Mirati Therapeutics, Inc. (MRTX) Research

Mirati Therapeutics, Inc. is a U.S.-based biotechnology firm operating at the clinical stage, committed to identifying and developing treatments that target the genetic and immunological factors driving cancer progression. Its pipeline features MRTX849, a KRAS G12C inhibitor currently undergoing Phase 1/2 clinical trials for a range of malignancies, including non-small cell lung, colorectal, and pancreatic cancers. Additionally, the company is advancing Sitravatinib, an investigational broad-spectrum kinase inhibitor, which has reached Phase 3 clinical trials specifically for non-small cell lung cancer. Mirati also has a KRAS G12D inhibitor program in its preclinical development phase. The company has forged a collaboration and licensing agreement with BeiGene, Ltd. for the development, manufacturing, and commercialization of sitravatinib. Established in 1995, Mirati Therapeutics, Inc. maintains its headquarters in San Diego, California.

Market snapshot

Symbol
MRTX
Price
$58.70
Day change
-0.17%
Market cap
$4.1B
P/E ratio
-4.46x
52-week range
27.3-64.41
Sector
Healthcare
Industry
Biotechnology
Analyst price target
$102.1

Peer companies

  • Alpine Immune Sciences, Inc. (ALPN)
  • CymaBay Therapeutics, Inc. (CBAY)
  • IVERIC bio, Inc. (ISEE)
  • Chinook Therapeutics, Inc. (KDNY)
  • MorphoSys AG (MOR)
  • Morphic Holding, Inc. (MORF)
  • Myovant Sciences Ltd. (MYOV)
  • Opthea Limited (OPT)

Recent insider activity

  • Boxer Capital, LLC — D-Return (30518 shares) on 2024-01-23
  • Boxer Capital, LLC — D-Return (1413475 shares) on 2024-01-23
  • Sharp Shalini — D-Return (4162 shares) on 2024-01-23
  • Sharp Shalini — D-Return (5252 shares) on 2024-01-23
  • Sharp Shalini — D-Return (6808 shares) on 2024-01-23

Open Mirati Therapeutics, Inc. (MRTX) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.